Tigenix gets EMA nod for off-the-shelf stem cell therapy in Crohn’s disease – BioWorld Online
Business Wire |
Tigenix gets EMA nod for off-the-shelf stem cell therapy in Crohn’s disease
BioWorld Online LONDON – Eight years on from securing the first EMA approval for an autologous cell therapy, Tigenix NV has done it again, getting the nod for the first allogeneic adipose-derived stem cell therapy, Alofisel (Cx601, darvadstrocel), in the treatment of … Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex …Nasdaq |
|
Cancer immunotherapy may work better in patients with specific genes
Science Daily Investigators at Columbia University’s Herbert Irving Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center-led by Naiyer Rizvi, MD, and Timothy Chan, MD, PhD-have been trying to understand why and have recently found how an individual … |
Medical Xpress |
Cancer immunotherapy may work better in patients with specific genes
Medical Xpress Investigators at Columbia University’s Herbert Irving Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center-led by Naiyer Rizvi, MD, and Timothy Chan, MD, PhD-have been trying to understand why and have recently found how an individual … |
Medical Xpress |
Cancer immunotherapy may work better in patients with specific genes
Medical Xpress Investigators at Columbia University’s Herbert Irving Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center-led by Naiyer Rizvi, MD, and Timothy Chan, MD, PhD-have been trying to understand why and have recently found how an individual … |
SMA News Today |
FDA Gives AveXis Thumbs Up to Launch Gene Therapy Study in SMA Type 2
SMA News Today The U.S. Food and Drug Administration (FDA) has given AveXis the green light to launch a Phase 1 study of its gene therapy, AVXS-101, in children with spinal muscular atrophy (SMA) Type 2. In contrast to the company’s earlier study in Type 1 SMA … |